Yudong D He
Overview
Explore the profile of Yudong D He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
6584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He Z, Glass M, Venkatesan P, Feser M, Lazaro L, Okada L, et al.
bioRxiv
. 2024 Nov;
PMID: 39554042
Some autoimmune diseases, including rheumatoid arthritis (RA), are preceded by a critical subclinical phase of disease activity. Proactive clinical management is hampered by a lack of biological understanding of this...
2.
Pandya R, He Y, Sweeney T, Hasin-Brumshtein Y, Khatri P
Genome Med
. 2023 Aug;
15(1):64.
PMID: 37641125
Background: Viral acute respiratory illnesses (viral ARIs) contribute significantly to human morbidity and mortality worldwide, but their successful treatment requires timely diagnosis of viral etiology, which is complicated by overlap...
3.
Hasin-Brumshtein Y, Sakaram S, Khatri P, He Y, Sweeney T
Sci Rep
. 2022 Feb;
12(1):2571.
PMID: 35173224
Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive liver disease that affects up to 30% of worldwide population, of which up to 25% progress to Non-Alcoholic SteatoHepatitis (NASH), a severe...
4.
Sakaram S, Hasin-Brumshtein Y, Khatri P, He Y, Sweeney T
Diagnostics (Basel)
. 2021 Oct;
11(10).
PMID: 34679598
Background: Anti-TNF-alpha (anti-TNFα) therapies have transformed the care and management of inflammatory bowel disease (IBD). However, they are expensive and ineffective in greater than 50% of patients, and they increase...
5.
He Y, Wohlford E, Uhle F, Buturovic L, Liesenfeld O, Sweeney T
J Pers Med
. 2021 Aug;
11(8).
PMID: 34442377
In response to the unmet need for timely accurate diagnosis and prognosis of acute infections and sepsis, host-immune-response-based tests are being developed to help clinicians make more informed decisions including...
6.
Glaab W, Holder D, He Y, Bailey W, Gerhold D, Beare C, et al.
Toxicol Sci
. 2021 Apr;
181(2):148-159.
PMID: 33837425
A new safety testing paradigm that relies on gene expression biomarker panels was developed to easily and quickly identify drug-induced injuries across tissues in rats prior to drug candidate selection....
7.
Zheng H, Rao A, Dermadi D, Toh J, Jones L, Donato M, et al.
Immunity
. 2021 Mar;
54(4):753-768.e5.
PMID: 33765435
Viral infections induce a conserved host response distinct from bacterial infections. We hypothesized that the conserved response is associated with disease severity and is distinct between patients with different outcomes....
8.
Thair S, He Y, Hasin-Brumshtein Y, Sakaram S, Pandya R, Toh J, et al.
iScience
. 2021 Jan;
24(1):101947.
PMID: 33437935
The pandemic 2019 novel coronavirus disease (COVID-19) shares certain clinical characteristics with other acute viral infections. We studied the whole-blood transcriptomic host response to severe acute respiratory syndrome coronavirus 2...
9.
Sweeney T, Liesenfeld O, Wacker J, He Y, Rawling D, Remmel M, et al.
Crit Care Med
. 2020 Nov;
49(2):e170-e178.
PMID: 33201004
Objectives: Complex critical syndromes like sepsis and coronavirus disease 2019 may be composed of underling "endotypes," which may respond differently to treatment. The aim of this study was to test...
10.
Turk J, Deaton A, Yin J, Stolina M, Felx M, Boyd G, et al.
Regul Toxicol Pharmacol
. 2020 Jun;
115:104697.
PMID: 32590049
Romosozumab (EVENITY™ [romosozumab-aqqg in the US]) is a humanized monoclonal antibody that inhibits sclerostin and has been approved in several countries for the treatment of osteoporosis in postmenopausal women at...